Kazuhiro Yamaguchi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Kazuhiro Yamaguchi has a total of 87 co-authors. Here are the top co-authors by number of shared publications:
Takao Tsuji
Department of Respiratory Medicine, Tokyo Medical University, Tokyo 160-0023, Japan
9 shared publicationsKazutetsu Aoshiba
Department of Respiratory Medicine, Tokyo Medical University Ibaraki Medical Center, Ibaraki 300-0395, Japan
8 shared publications- Kazutetsu Aoshiba
Tokyo Medical University Ibaraki Medical Center Department of Respiratory Medicine Ibaraki, Japan
7 shared publications - Hiroyuki Nakamura
Tokyo Medical University Ibaraki Medical Center Department of Respiratory Medicine Ibaraki, Japan
6 shared publications Atsushi Nagai
The First Department of Medicine, Tokyo Women's Medical University, Tokyo, Japan
5 shared publications- Ryota Kikuchi
Department of Respiratory Medicine Tokyo Medical University Hospital Tokyo Japan
4 shared publications
Latest Publications
- Open Access
- 15 August 2023
- Published by Springer Nature in npj Primary Care Respiratory Medicine
- Vol. 33 (1) , 1-7
Interaction of BMI and respiratory status in obstructive sleep apnea, a cross-sectional COPD study
This cross-sectional study of 136 patients with chronic obstructive pulmonary disease (COPD) investigated the mechanism underlying overlap syndrome, defined as coexisting COPD and obstructive sleep apnea (OSA). OSA was defined as a respiratory event index (REI) ≥ 5 events/h, determined using type-3 portable monitors. The mean REI was 12.8 events/h. Most participants (60.1%) had mild OSA (REI: 5–15 events/h). The REI was positively correlated with forced expiratory volume in one second (%FEV1) (r = 0.33, p < 0.001), body mass index (BMI) (r = 0.24, p = 0.005), and fat-free mass index (r = 0.31, p = 0.005), and negatively correlated with residual volume divided by total lung capacity (r = −0.27, p = 0.003). Receiver-operating characteristic curve analysis revealed an optimal BMI cutoff of 21.96 kg/m2 for predicting moderate/severe OSA. A BMI ≥ 21.96 kg/m2 was associated with OSA among participants with %FEV1 ≥ 50%, but not those with %FEV1 < 50%. This study revealed an interaction between airflow limitation and hyperinflation, nutritional status, and OSA.
- 15 August 2023
- Published by Springer Nature in npj Primary Care Respiratory Medicine
- Vol. 33 (1) , 1-7
Open AccessInteraction of BMI and respiratory status in obstructive sleep apnea, a cross-sectional COPD study
This cross-sectional study of 136 patients with chronic obstructive pulmonary disease (COPD) investigated the mechanism underlying overlap syndrome, defined as coexisting COPD and obstructive sleep apnea (OSA). OSA was defined as a respiratory event index (REI) ≥ 5 events/h, determined using type-3 portable monitors. The mean REI was 12.8 events/h. Most participants (60.1%) had mild OSA (REI: 5–15 events/h). The REI was positively correlated with forced expiratory volume in one second (%FEV1) (r = 0.33, p < 0.001), body mass index (BMI) (r = 0.24, p = 0.005), and fat-free mass index (r = 0.31, p = 0.005), and negatively correlated with residual volume divided by total lung capacity (r = −0.27, p = 0.003). Receiver-operating characteristic curve analysis revealed an optimal BMI cutoff of 21.96 kg/m2 for predicting moderate/severe OSA. A BMI ≥ 21.96 kg/m2 was associated with OSA among participants with %FEV1 ≥ 50%, but not those with %FEV1 < 50%. This study revealed an interaction between airflow limitation and hyperinflation, nutritional status, and OSA.
- 1 October 2021
- Published by Elsevier in Pulmonary Pharmacology & Therapeutics
- Vol. 70, 102052
Differential effects of dexamethasone and roflumilast on asthma in mice with or without short cigarette smoke exposure
- 1 October 2021
- Published by Elsevier in Pulmonary Pharmacology & Therapeutics
- Vol. 70, 102052
Differential effects of dexamethasone and roflumilast on asthma in mice with or without short cigarette smoke exposure
- Open Access
- 3 May 2021
- Published by Wiley in Thoracic Cancer
- Vol. 12 (11) , 1681-1689
Glasgow prognostic score for prediction of chemotherapy‐triggered acute exacerbation interstitial lung disease in patients with small cell lung cancer
Background: Predicting the incidence of chemotherapy‐triggered acute exacerbation of interstitial lung disease (AE‐ILD) in patients with lung cancer is important because AE‐ILD confers a poor prognosis. The Glasgow prognostic score (GPS), which is an inflammation‐based index composed of serum levels of C‐reactive protein and albumin, predicts prognosis in patients with small cell lung cancer (SCLC) without ILD. In this study, we investigated AE‐ILD and survival outcome based on the GPS in patients with ILD associated with SCLC who were receiving chemotherapy.Methods: Medical records of patients who received platinum‐based first‐line chemotherapy between June 2010 and May 2019 were retrospectively reviewed to compare the incidence of AE‐ILD and overall survival (OS) between GPS 0, 1, and 2.Results: Among our cohort of 31 patients, six (19.3%) experienced chemotherapy‐triggered AE‐ILD. The AE‐ILD incidence increased from 9.5% to 25.0% and 50.0% with increase in GPS of 0, 1, and 2, respectively. Univariate and multivariate analyses revealed remarkable associations between GPS 2 and both AE‐ILD (odds ratio for GPS 2, 18.69; p = 0.046) and prognosis (hazard ratio of GPS 2, 13.52; p = 0.002). Furthermore, median OS in the GPS 0, 1, and 2 groups was 16.2, 9.8, and 7.1 months, respectively (p < 0.001).Conclusions: Our results suggest that GPS 2 is both a predictor of risk of chemotherapy‐triggered AE‐ILD and a prognostic indicator in patients with ILD associated with SCLC. We propose that GPS may be used as a guide to distinguish chemotherapy‐tolerant patients from those at high risk of AE‐ILD.
- 3 May 2021
- Published by Wiley in Thoracic Cancer
- Vol. 12 (11) , 1681-1689
Open AccessGlasgow prognostic score for prediction of chemotherapy‐triggered acute exacerbation interstitial lung disease in patients with small cell lung cancer
Background: Predicting the incidence of chemotherapy‐triggered acute exacerbation of interstitial lung disease (AE‐ILD) in patients with lung cancer is important because AE‐ILD confers a poor prognosis. The Glasgow prognostic score (GPS), which is an inflammation‐based index composed of serum levels of C‐reactive protein and albumin, predicts prognosis in patients with small cell lung cancer (SCLC) without ILD. In this study, we investigated AE‐ILD and survival outcome based on the GPS in patients with ILD associated with SCLC who were receiving chemotherapy.Methods: Medical records of patients who received platinum‐based first‐line chemotherapy between June 2010 and May 2019 were retrospectively reviewed to compare the incidence of AE‐ILD and overall survival (OS) between GPS 0, 1, and 2.Results: Among our cohort of 31 patients, six (19.3%) experienced chemotherapy‐triggered AE‐ILD. The AE‐ILD incidence increased from 9.5% to 25.0% and 50.0% with increase in GPS of 0, 1, and 2, respectively. Univariate and multivariate analyses revealed remarkable associations between GPS 2 and both AE‐ILD (odds ratio for GPS 2, 18.69; p = 0.046) and prognosis (hazard ratio of GPS 2, 13.52; p = 0.002). Furthermore, median OS in the GPS 0, 1, and 2 groups was 16.2, 9.8, and 7.1 months, respectively (p < 0.001).Conclusions: Our results suggest that GPS 2 is both a predictor of risk of chemotherapy‐triggered AE‐ILD and a prognostic indicator in patients with ILD associated with SCLC. We propose that GPS may be used as a guide to distinguish chemotherapy‐tolerant patients from those at high risk of AE‐ILD.
- 1 November 2020
- Published by Elsevier in Respiratory Physiology & Neurobiology
- Vol. 282, 103517
Can DLNO/DLCO ratio offset prejudicial effects of functional heterogeneities in acinar regions?
- 1 November 2020
- Published by Elsevier in Respiratory Physiology & Neurobiology
- Vol. 282, 103517
Can DLNO/DLCO ratio offset prejudicial effects of functional heterogeneities in acinar regions?
- 1 August 2020
- Published by Springer Nature
- p. 95-116
Convective and Diffusive Mixing in Lower and Acinar Airways: Is Diffusive Mixing Effective in the Lung Periphery?
- 1 August 2020
- Published by Springer Nature
- p. 95-116
Convective and Diffusive Mixing in Lower and Acinar Airways: Is Diffusive Mixing Effective in the Lung Periphery?
- 1 May 2020
- Published by Elsevier in Respiratory Physiology & Neurobiology
- Vol. 276, 103415
What are appropriate values of relative krogh diffusion Constant of NO against CO and of theta-NO in alveolar septa?
- 1 May 2020
- Published by Elsevier in Respiratory Physiology & Neurobiology
- Vol. 276, 103415
What are appropriate values of relative krogh diffusion Constant of NO against CO and of theta-NO in alveolar septa?
- Open Access
- 27 January 2019
- Published by Baishideng Publishing Group Inc. in World Journal of Respirology
- Vol. 9 (2) , 8-28
Anatomical backgrounds on gas exchange parameters in the lung
Anatomical backgrounds on gas exchange parameters in the lung
- 27 January 2019
- Published by Baishideng Publishing Group Inc. in World Journal of Respirology
- Vol. 9 (2) , 8-28
Open AccessAnatomical backgrounds on gas exchange parameters in the lung
Anatomical backgrounds on gas exchange parameters in the lung